Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention
National Institute for Health and Clinical Excellence
Record ID 32011000084
English
Authors' recommendations:
Prasugrel in combination with aspirin is recommended as an option for preventing atherothrombotic events in people with acute coronary syndromes having percutaneous coronary intervention, only when:• immediate primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction is necessary or• stent thrombosis has occurred during clopidogrel treatment or• the patient has diabetes mellitus.People currently receiving prasugrel for treatment of acute coronary syndromes whose circumstances do not meet the criteria above should have the option to continue therapy until they and their clinicians consider it appropriate to stop.
Details
Project Status:
Completed
URL for project:
http://www.nice.org.uk/nicemedia/live/12324/45849/45849.pdf
Year Published:
2009
URL for published report:
http://www.nice.org.uk/TA182
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England
MeSH Terms
- Angioplasty, Balloon, Coronary
- Cost-Benefit Analysis
- Practice Guidelines as Topic
- Prasugrel Hydrochloride
- Acute Coronary Syndrome
- Evidence-Based Medicine
- Piperazines
- Platelet Aggregation Inhibitors
- Thiophenes
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.